Enjoy complimentary customisation on priority with our Enterprise License!
The non-insulin diabetes therapeutics market size is estimated to grow at a CAGR of 10.82% between 2022 and 2027. The market size is forecast to increase by USD 31,251.55 million. The growth of the market depends on several factors, including the increasing number of people with type 2 diabetes, the growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.
This non-insulin diabetes therapeutics market report extensively covers market segmentation by type (DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The increasing number of people with type 2 diabetes is notably driving the market growth, although factors such as concerns about safety may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
An increasing number of people with type 2 diabetes is the key factor driving the growth of the global non-insulin diabetes therapeutics market. Type 2 diabetes is caused by the ineffective use of insulin produced by the body. It is the most common form of diabetes worldwide. Obesity and lack of exercise are the most common causes of type 2 diabetes. Type 2 diabetes is caused by hyperglycemia and metabolic changes due to abnormal insulin secretion and action. Until the early 2000s, the disease was common only in adults. However, the prevalence of type 2 diabetes in children is increasing.
The early diagnosis of type 2 diabetes is often a challenge due to the generic symptoms associated with the disease. Hence, once the disease is diagnosed, it is essential to provide advanced medications. Different antihyperglycemic drugs are used alone or in combination with other drugs, such as insulin, to treat type 2 diabetes. The initial steps of treatment include weight loss plans, lifestyle changes, and the administration of metformin. The ADA and the European Association for the Study of Diabetes (EASD) recommend a patient-specific treatment approach to enhance glycemic control to treat type 2 diabetes. This is to avoid weight gain and hypoglycemia. Hence, the increasing number of people with type 2 diabetes will drive the growth of the global non-insulin diabetes therapeutics market during the forecast period.
Innovations in therapies are the primary trend shaping the global non-insulin diabetes therapeutics market growth. Several vendors are introducing advanced therapies to treat diabetes. Incretins are GLP-1 and glucose-dependent insulinotropic polypeptides (GIP), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIP stimulate the beta cells of the pancreas, which contribute 60% of the insulin secreted after a meal. Type 2 diabetes reduces the secretion of GLP-1 and reduces responsiveness to GIP. The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. Two incretin-based drug classes are used to treat people with type 2 diabetes. These include oral DPP4 inhibitors and GLP-1 receptor agonists.
The pathophysiology of type 2 diabetes involves at least seven organs and tissues, which include the brain, liver, pancreas, intestines, kidneys, fat, and muscles. No single medication addresses all seven organs and tissues. Most people require more than one medication to treat the disease. Hence, drugs with unique and complementary MoA are required. Therapeutics such as DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR provide therapeutic options with novel MoA. They also prevent weight gain and reduce the risk of hypoglycemia. Though all medications are not appropriate for all people, they offer healthcare providers options to individualize treatments and optimize care for patients. Hence, the market is expected to grow during the forecast period.
Concerns about safety are a major challenge to the growth of the global non-insulin diabetes therapeutics market. Several non-insulin diabetes drugs are currently under review by the US FDA due to safety concerns. For example, in 2017, the U.S. Food and Drug Administration added a boxed warning to the label of Janssen type 2 diabetes medication because it increases the risk of leg and foot amputations. That's why the company's type 2 diabetes medications like Invokana, Invokamet, and Invokamet XR should include a risk statement in the box next to the canagliflozin drug label.
In 2015, the US FDA also revised the labels of SGLT2 inhibitors to include warnings about the risk of high levels of acid in the blood and the possibility of severe urinary tract infections (UTIs). Such initiatives are increasing awareness about the safety of certain drugs. However, they are a challenge for the growth of the global non-insulin diabetes therapeutics market as vendors must make significant investments in R&D to develop safe drugs. Hence, safety concerns may hamper the growth of the market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Non-insulin Diabetes Therapeutics Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories: The company offers non insulin diabetes therapeutics solutions such as Abbotts Freestyle libre system significantly reduces HBA1C levels in people with type 2 diabetes.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the DPP4 inhibitors segment will be significant during the forecast period. DPP4 inhibitors are therapeutics that reduce high blood glucose levels. They are widely used to treat type 2 diabetes. DPP4 inhibitors improve blood glucose control and reduce fasting and postprandial blood glucose levels without causing weight gain. The changes of hypoglycemia are low when using DPP4 inhibitors unless they are combined with other therapies that cause hypoglycemia.
Get a glance at the market contribution of various segments View the PDF Sample
The DPP4 inhibitors segment was valued at USD 11,810.09 million in 2017 and continued to grow until 2021. DPP4 inhibitors block the action of DPP4, an enzyme that destroys incretin. As incretin helps the body produce more insulin when needed and reduces the amount of glucose produced by the body when not required, its destruction could cause type 2 diabetes. These hormones are released throughout the day, and their levels increase during the consumption of food. Therefore, DPP4 inhibitors are required to stabilize type 2 diabetes. Hence, their adoption is high across the world. Such factors will increase segment growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Several vendors offer non-insulin diabetes therapeutics in North America, which is increasing awareness and the availability of non-insulin diabetes therapeutics in the region. The vendors are focusing on product development and clinical trials. Hence, the availability of advanced therapeutics and delivery techniques is improving in the region. However, several stringent regulations have been implemented in the region. For instance, in 2008, the US FDA published guidance for the industry, which recommended that new drug applications (NDAs) for diabetes should include evidence that they do not increase the risk of cardiovascular events. Hence, vendors must make significant investments in R&D to develop therapeutics that are safe.
In 2020, the outbreak of COVID-19 affected the economies of various countries in North America, especially the US. However, the initiation of large-scale vaccination drives led to the lifting of restrictions in 2021. This has resulted in the resumption of normal treatments, which has increased the demand for non-insulin diabetes therapeutics in the region. Such factors are expected to drive the growth of the regional market during the forecast period.
The non-insulin diabetes therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global non-insulin diabetes therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Non-insulin Diabetes Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
172 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.82% |
Market growth 2023-2027 |
USD 31,251.55 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
10.02 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and India |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AstraZeneca PLC, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.